Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Broker Meets Biotech – Perth (September 2014)
21 slides from Pyc Therapeutics's conference presentation, Sep 18, 2014
Slide 1: Phylogica – Broker Meets Biotech Perth
For personal use only Phylogica Broker Meets Biotech – Perth (PYC:ASX) Harnessing biodiversity for peptide therapeutics
Slide 2: Disclaimer
Disclaimer The purpose of the presenta.on is to provide an update of the business of Phylogica Limited (ASX:PYC) For personal use only [‘Phylogica’]. These slides have been prepared as a presenta.on aid only and the informa.on they contain may require further explana.on and/or clarifica.on. According
Slide 3: About Phylogica
About Phylogica § Owns unique proprietary class of pep.de therapeu.cs (Phylomers®) For personal use only – Pep.de market forecast: $25B by 2018 § Extensive & mature IP estate with mul.ple granted patents § Game changing: ‘Best-‐in-‐Class’ pep.des for delivering drugs inside cells § ‘Discovery
Slide 4: Corporate overview
Corporate overview § PYC Share Price: 1.7c For personal use only § Market Cap: $17m § Stock Tightly Held: >50% stock owned by top 15 shareholders § Strong cash posiGon: – Successful $6.1m cap raise Jan 2014 – Cash at 30 Jun: $3,718,659 – R&D tax rebate + forecast revenues extends cash runway to
Slide 5: Discovery partnership model
Discovery partnership model § For personal use only Fee-‐for-‐service model generates revenues to achieve Cash Sustainability § Drug discovery engine provides mul.ple early-‐stage partnership/discovery opportuni.es § Alliance revenues used to subsidise in-house oncology program Discovery Co-de
Slide 6: Partnerships: focus on intracellular delivery of biologics
Partnerships: focus on intracellular delivery of biologics For personal use only CNS Delivery Cell penetrating Intracellular Drug Vaccines peptides Delivery Cancer Antimicrobials Focus/DifferenGaGon 6
Slide 7: Partnerships accelerate platform development
For personal use only Partnerships accelerate plaLorm development IP progression ($2.3m) ($540K) New IP R&D partnerships ($2.4m) New IP New IP Time § Phylogica partnerships have driven major plaLorm advances and generated novel IP 7
Slide 8: Technology Introduction
For personal use only Technology IntroducGon
Slide 9: Phylomer peptides: sourced from nature
Phylomer peptides: sourced from nature For personal use only Microbial Genomes Phylomer Libraries (High quality building blocks) 9
Slide 10: Using Phylomers to address an unmet need
Using Phylomers to address an unmet need Market for TherapeuGc Drugs For personal use only Small Molecules Biologics (Conven.onal drugs) (Smart Drugs) 50% 40% Healthy cell Biologics: Small molecule drugs: -‐ Specific drug delivery -‐ Nonspecific Disease cell -‐ Reduced toxicity -‐ Side effects -‐
Slide 11: Majority of drug targets are inside cells
Majority of drug targets are inside cells Intracellular Drug Targets For personal use only Small Molecule Drugs (10%) Undrugged targets (90%) Biologics? § How do we get smart drugs inside cells?
Slide 12: Peptides: the best of both worlds
PepGdes: the best of both worlds For personal use only Large Biologics (Smart drugs) Cell PenetraGng Targets Phylomer PepGdes Specific (Smart) Small Molecule Drugs Size 12
Slide 13: Cell Penetrating Phylomers: delivering biologics cargoes inside cells
Cell PenetraGng Phylomer (CPPs): delivering biologics cargoes inside cells For personal use only PotenGal to expand the druggable landscape by >10-‐fold!! 13
Slide 14: The Problem: Drugs are trapped in endosomes
The Problem: Drugs are trapped in endosomes For personal use only Drug Drug Drug contacts cell Budding membrane endosome Contact triggers formaGon of endosomes Cell Membrane Endosome Drug 99.9% of drug trapped in endosome Cell Membrane
Slide 15: The Solution: PYC's Endosomal Escape Trap
For personal use only The SoluGon: PYC’s Endosomal Escape Trap Tag Phylomer Phylomer Untagged Phylomer Escaped Phylomer § Phylogica’s endosome escape trap for capture of novel cell penetra.ng Phylomers
Slide 16: 'Best-in-class' Phylomers for delivering drugs inside cells
‘Best-‐in-‐class’ Phylomers for delivering drugs inside cells For personal use only 25-‐fold High receptor-‐expressing cells: 50 transfec.on efficiency: 70.3% 10µM protein 40 3µM protein efficiency cells (Q3) (% Green Cells) single cell population 30 ‘Best in Class’ Phylomer CPP % green viable Deliv
Slide 17: Focus: Phylogica's Integrated Drug Discovery Solution
Focus: Phylogica’s Integrated Drug Discovery SoluGon For personal use only ✔ Endosomal escape Phylomer Discovery Engine DisrupGve technology Cell Penetra.ng Phylomer Smart 10X expansion Phylomers Drugs in druggable landscape ✔ 17
Slide 18: Developing Phylomer drugs to treat cancer
Developing Phylomer drugs to treat cancer For personal use only § Unmet need for drugs against breast cancer targets intractable to conven.onal therapies § Phylogica’s plarorm accelerates path to drug discovery § Rapid access to high-‐value commercial inflexion points 18
Slide 19: Upcoming commercial milestones
Upcoming commercial milestones For personal use only § Discovery Partnerships – Genentech II (2014/15) – New discovery alliances § Oncology programme – Early 2015: In vitro data – Key value inflexion, early-‐stage partnering opportunity. – Late 2015: In vivo data -‐ Licensing opportunity 19
Slide 20: Phylogica: well-positioned to return value for investors
Phylogica: well-‐posiGoned to return value for investors For personal use only Addressing unmet need to deliver smart drugs inside cells PlaLorm validated by mulGple partnerships Access to mulGple revenue streams Cash/Capital Efficiency 20
Slide 21: Contact Details
Dr. Richard Hopkins Contact Details Dr. Paul Wam Chief ExecuGve Officer Chief ScienGfic Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 For personal use only Fax: +61 8 9489 7700 Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.phylogic
Phylogica — Broker Meets Biotech – Perth (September 2014) on 6ix